Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...

(Reuters) - Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously ...

have been withdrawn in bladder cancer as a result. Gilead said Trodelvy’s safety profile in the TROPHY study is consistent with previous observations in metastatic UC and other tumour types.

notably triple-negative breast and bladder cancer therapy Trodelvy (sacituzumab govitecan), which Gilead acquired as part of its $21 billion takeover of Immunomedics in 2020. Two of the three ...

A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and ...

Cancer Screening Guidelines Validated for Dermatomyositis Most of the cancers were detected using standard age- and sex-based cancer screenings, suggesting the potential for overscreening in this ...